Brian A. Bruckner

Brian A. Bruckner

Auto-generated profile, based on publicly available information

Brian A. Bruckner

Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2014 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
BBBrian A Bruckner
Brian A Bruckner
LBLance N Blau
Lance N Blau
LRLimael Rodriguez
Limael Rodriguez
ESErik E Suarez
Erik E Suarez
UNUy Q Ngo
Uy Q Ngo
MLMatthias Loebe
Matthias Loebe
Topical hemostatic agents are used to reduce bleeding and transfusion need during cardiothoracic surgery. We report our experience with Arista® AH Absorbable Hemostatic Particles (Arista® AH), a novel plant-based microporous polysaccharide hemostatic powder.

25 November 2019 in Journal of Cardiac Surgery
Verified
Journal Article
Open access
PDF file
NDNicholas C. Dang
Nicholas C. Dang
AAAbbas Ardehali
Abbas Ardehali
BBBrian A. Bruckner
Brian A. Bruckner
PPPatrick E. Parrino
Patrick E. Parrino
DGDaniel L. Gillen
Daniel L. Gillen
WSWilliam D. Spotnitz
William D. Spotnitz
Aim This trial compared the hemostatic performance of a novel combination powder (CP) to a control hemostatic matrix (HM) in cardiothoracic operations. Methods Patients meeting eligibility criteria were enrolled after providing informed consent. Subjects were randomized intraoperatively to receive CP (HEMOBLAST Bellows; Biom'up, France) or HM (FLOSEAL Hemostatic Matrix; Baxter Healthcare Corporation, Hayward, CA). Bleeding was assessed using a clinically validated, quantitative bleeding severity scale. The primary endpoint was total time to hemostasis (TTTH), from the start of device preparation, as an indicator of when a surgeon asks for a surgical hemostat until hemostasis was achieved. TTTH at 3 minutes was utilized for the primary analysis, while TTTH at 5 minutes was considered as a secondary endpoint. Results A total of 105 subjects were enrolled across four institutions. The primary efficacy endpoint for the superiority of CP relative to HM for success at achieving hemostasis within 3 minutes was met, with 64.2% of the CP group achieving hemostasis compared with 9.6% of the HM group, a difference of 54.54% (37.4%‐71.6%; P < .001 for superiority). The secondary efficacy endpoint was also met, with 92.5% of the CP group achieving hemostasis at 5 minutes versus 44.2% in the HM group, a difference of 48.2% (31.1%‐65.4%; P < .001 for noninferiority). There were no device‐related adverse events. Conclusions In this multicenter, randomized, controlled trial, comparison of CP to HM revealed CP superiority and noninferiority for TTTH at 3 and 5 minutes, respectively.

1 June 2016 in Texas Heart Institute Journal
Verified
Journal Article
Closed access
BBBrian A. Bruckner
Brian A. Bruckner
WSWalid K. Abu Saleh
Walid K. Abu Saleh
OJOdeaa Al Jabbari
Odeaa Al Jabbari
JCJack G. Copeland
Jack G. Copeland
JEJerry D. Estep
Jerry D. Estep
MRMichael J. Reardon
Michael J. Reardon
Primary cardiac sarcomas, although rare, are aggressive and lethal, requiring thorough surgical resection and adjuvant chemotherapy for the best possible outcome. We report the case of a 32-year-old woman who underwent total artificial heart implantation for right-sided heart failure caused by right ventricular angiosarcoma. For the first several weeks in intensive care, the patient recovered uneventfully. However, a postoperative liver biopsy indicated hepatocellular injury consistent with preoperative chemotherapy. She developed continuing liver failure, from which she died despite good cardiac function.

1 July 2008 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
JJJama Jahanyar
Jama Jahanyar
KYKeith A. Youker
Keith A. Youker
GTGuillermo Torre-Amione
Guillermo Torre-Amione
MKMichael M. Koerner
Michael M. Koerner
BBBrian Bruckner
Brian Bruckner
MLMatthias Loebe
Matthias Loebe

26 April 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AGAshrith Guha
Ashrith Guha
BHBashar Hannawi
Bashar Hannawi
ACAna Cruz-Solbes
Ana Cruz-Solbes
DNDuc Nguyen
Duc Nguyen
BBBrian A. Bruckner
Brian A. Bruckner
JEJerry D. Estep
Jerry D. Estep
The new allocation criteria classify patients on veno-arterial extracorporeal membranous oxygenation (VA-ECMO) as the highest priority for receiving orthotopic heart transplantation (OHT) especially if they are considered not candidates for ventricular assist devices. The outcomes of patients who receive ventricular assist devices (VADs) after being listed for heart transplantation with VA-ECMO is unknown. We analyzed 355 patients listed for OHT with VA-ECMO from the United Network for Organ Sharing database from 2006 to 2014. Univariate and multivariate Cox proportional-hazards models were used to determine the contribution of prognostic variables to the outcome. Thirty-three patients (9.3%) received VADs (15 dischargeable, 7 non-dischargeable VADs). The VAD and non-VAD groups had similar listing characteristics except that the VAD group were more likely to have non-ischemic cardiomyopathy (48.5% vs. 25.2%), and less likely to be obese (6.1% vs. 25.2%) or have a history of prior organ transplant (3% vs. 31.1%). Patients who underwent VAD implantation had more days on the list (median 189 vs. 14 days) compared to the non-VAD group. Amongst the patients who had VADs, (25/33) 75.5% patients were subsequently transplanted with similar post-transplant survival compared to the non-VAD group (72% vs. 60.5%; p = 0.276). Predictors of one-year post-transplant mortality included panel reactive antibodies (PRA) class I ≥ 20%, recipient smoking history, increased serum creatinine and total bilirubin. Therefore, a small proportion of patients listed for transplantation with VA ECMO undergo VAD implantation. Their waitlist survival is better than non-VAD group but with similar post-transplant survival.

26 July 2019 in Journal of Cardiac Surgery
Verified
Journal Article
Open access
BBBrian A. Bruckner
Brian A. Bruckner
UNUy Ngo
Uy Ngo
MRMahesh Ramchandani
Mahesh Ramchandani
ESErik Suarez
Erik Suarez
SASamir Awad
Samir Awad
MRMichael Reardon
Michael Reardon
Postoperative bleeding complications are associated with less favorable outcomes in cardiac surgery and contribute to excessive overall healthcare costs. HEMOBLAST (Biom'up, Lyon, France) (HB) is a novel ready-to-use hemostatic powder that consists of porcine collagen, bovine chondroitin sulfate, and human pooled plasma thrombin that may help reduce surgical bleeding. The aim of this study was to describe the techniques of application for this new combination powder-based hemostat, HB, and demonstrate its use employing photographs of application methods during cardiac procedures. The initial 24 procedures in which HB was used at our institution included: left ventricular assist device (LVAD) insertions, lung transplants, heart transplants, aortic valve replacements, coronary artery bypass grafting, and mitral valve repair. Hemostasis was achieved in all cases and there were no instances of mediastinitis, sternal infections, allergic reactions, or 30-day mortality. This report describes the best methods of application of HB including use for treatment of mediastinal bleeding in a re-operative procedure in a patient on antiplatelet agents and sternal bleeding during an LVAD insertion. Proper application can facilitate excellent hemostasis using this powder. HB is a novel powder-based multiple component hemostatic agent that promotes focal or large area hemostasis. We have presented the techniques of use that are important to the successful application of HB to facilitate hemostasis.